Imunon

IMNN

Market cap $12.4M

LAWRENCEVILLE, N.J., Dec. 30, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that it has entered into a securities purchase agreement with a single healthcare-focused institutional investor for the purchase and sale of 1,939,114 shares of common stock (or pre-funded warrants in-lieu thereof), together with warrants to purchase up to an aggregate of 1,939,114 shares of common stock, in a registered direct offering priced at-the-market under Nasdaq rules.

Enrollment in the Pivotal Phase 3 OVATION 3 Study Advances Company Toward Future BLA Filing New Data from MRD Study Reinforces IMNN-001's Promise as a Potential Breakthrough Immunotherapy LAWRENCEVILLE, N.J., Dec. 29, 2025 (GLOBE NEWSWIRE) -- IMUNON , Inc. (Nasdaq: IMNN) Dear Valued Shareholders, 2025, A Year of Momentum: Advancing Toward a Potential Breakthrough in Ovarian Cancer Treatment As we close out 2025, I am excited to reflect on a year marked by significant clinical progress, robust data validation, and strategic execution that has significantly strengthened IMUNON's position.

Imunon, Inc. ( IMNN ) Q3 2025 Earnings Call November 13, 2025 11:00 AM EST Company Participants Stacy Lindborg - President, CEO & Director Douglas V. Faller - Chief Medical Officer Kimberly Graper - CFO and Principal Financial & Accounting Officer Khursheed Anwer - Executive VP & Chief Scientific Officer Conference Call Participants David Bautz - Zacks Small-Cap Research James Molloy - Alliance Global Partners, Research Division Emily Bodnar - H.C.

R&D Day showcased remarkable Investigator optimism, continued strengthening supportive data, and significant progress with Phase 3 OVATION 3 Study in pursuit of first frontline immunotherapy for advanced ovarian cancer

Imunon, Inc. ( IMNN ) Discusses IMNN-001 Immunotherapy Progress and Milestones in OVATION 3 Ovarian Cancer Study November 10, 2025 8:00 AM EST Company Participants Stacy Lindborg - President, CEO & Director Douglas V. Faller - Chief Medical Officer Conference Call Participants Premal Thaker Amir Jazaeri Giorgio Paulon James Molloy - Alliance Global Partners, Research Division Emily Bodnar - H.C.

Webcast Recording and Symposium Slides Now Available LAWRENCEVILLE, N.J., Nov. 10, 2025 (GLOBE NEWSWIRE) -- IMUNON , Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today hosted a compelling public webcast, where cancer key opinion leaders, principal investigators from the Phase 3 OVATION 3 and Phase 2 minimal residual disease (MRD) trials, clinicians, statistical experts and IMUNON executives shared critical insights into the disease and translational data, along with compelling clinical data highlighting the significant potential of IMNN-001 for women with advanced ovarian cancer.

Event being held today at 8:00 a.m. ET in New York City features presentations from Ovarian Cancer Key Opinion Leaders, Clinicians, Statistical Experts, and IMUNON executives Investors, stakeholders, analysts and those interested in advances in ovarian cancer treatment and women's health are encouraged to attend, either In-person or virtually LAWRENCEVILLE, N.J.

Investors and stakeholders invited to attend in person in New York City or via live webcast on Monday, November 10th at 8:00 a.m. ET

LAWRENCEVILLE, N.J., Nov. 06, 2025 (GLOBE NEWSWIRE) -- IMUNON , Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that the Company will host a conference call at 11:00 a.m.

Investor event in New York City to provide update on pivotal Phase 3 study of IMNN-001; offering in-person or virtual attendance on November 10, 2025